Abstract
Carbamazepine (CBZ) is the antiepileptic drug of choice for partial and tonic-clonic seizure. CBZ is metabolized by the cytochrome P450 (CYP) system, particularly the isoforms CYP3A4 and CYP3A5. A number of allelic variants have been described for CYP3A4 and CYP3A5 potentially affecting the expression/activity of the enzymes with influences on drug metabolism. In order to evaluate the impact of CYP3A polymorphisms on CBZ plasma levels, 29 epileptic patients in CBZ therapy at steady-state were genotyped for CYP3A4 (*1B, *3, *4) e and CYP3A5 (*2,*3,*6) and the CBZ plasma levels measured.
Translated title of the contribution | Impact of CYP3A polymorphism on carbamazepine plasmatic levels |
---|---|
Original language | Italian |
Pages (from-to) | 205-207 |
Number of pages | 3 |
Journal | Bollettino - Lega Italiana contro l'Epilessia |
Issue number | 140 |
Publication status | Published - Apr 2010 |
ASJC Scopus subject areas
- Clinical Neurology